Please use this identifier to cite or link to this item: https://doi.org/10.2174/138161206777947696
Title: Targeting t-cell adhesion molecules for drug design
Authors: Jois, S.D.S. 
Jining, L.
Nagarajarao, L.M.
Keywords: Alefacept
CD2
Cell adhesion molecules
Efalizumab
ICAM-1
LFA-1
LFA-3
Issue Date: Aug-2006
Citation: Jois, S.D.S., Jining, L., Nagarajarao, L.M. (2006-08). Targeting t-cell adhesion molecules for drug design. Current Pharmaceutical Design 12 (22) : 2797-2812. ScholarBank@NUS Repository. https://doi.org/10.2174/138161206777947696
Abstract: Adhesion molecules participate in many stages of immune response; they regulate leukocyte circulation, lymphoid cell homing to tissues and inflammatory sites, migration across endothelial cells and T-cell stimulation. During T-cell immune response, adhesion molecules form a specialized junction between T-cell and the antigen presenting cell. Thus, many researchers have focused their attention on targeting adhesion molecules for developing therapeutic agents. Most of these efforts are intended to develop drugs for autoimmune and inflammatory diseases. Therapeutic agents like efalizumab and alefacept have been approved by the FDA for the treatment of inflammatory autoimmune diseases. This review focuses on some of the basic aspects and importance of adhesion molecules, recent understanding of the structure of adhesion molecules, and the targeted therapeutic agents. © 2006 Bentham Science Publishers Ltd.
Source Title: Current Pharmaceutical Design
URI: http://scholarbank.nus.edu.sg/handle/10635/106712
ISSN: 13816128
DOI: 10.2174/138161206777947696
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on May 19, 2018

WEB OF SCIENCETM
Citations

6
checked on Apr 3, 2018

Page view(s)

35
checked on May 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.